

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/928,262
Filing Date	August 10, 2001
First Named Inventor	Havenga et al.
Group Art Unit	1635
Examiner Name	B. Whiteman
Attorney Docket Number	2578-4509 111S

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PL		✓ ARAI et al., Adenovirus Vector-Mediated Gene Transduction to Chondrocytes: In Vitro Evaluation of Therapeutic Efficacy of Transforming Growth Factor-beta1 and Heat Shock Protein 70 Gene Transduction, Journal of Rheumatology, 1997, pp. 1787-95, Vol. 24, No. 9.	
		✓ ARAI et al., Control of Delivered Gene Expression in Chondrocytes Using Heat Shock Protein 70B Promoter, Journal of Rheumatology, August 1999, pp. 1769-74, Vol. 26, No. 8.	
		✓ BARAGI et al., Transplantation of Transduced Chondrocytes Protects Articular Cartilage from Interleukin 1-Induced Extracellular Matrix Degradation, Journal of Clinical Investigation, 1995, pp. 2454-60, Vol. 96, No. 5.	
		✓ DUPREZ et al., Overexpression of BMP-2 and BMP-4 alters the size and shape of developing skeletal elements in the chick limb, Mechanisms of Development, 1996, pp. 145-57, Vol. 57, No. 2.	
DL		✓ SMITH et al., Genetic Enhancement of Matrix Synthesis By Articular Chondrocytes, Arthritis and Rheumatism, May 2000, pp. 1156-64, Vol. 43, No. 5.	

Examiner
Signature

B. Whiteman

Date
Considered

7/16/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.